The rapidly expanding global healthcare industry has created intensifying demand for efficient, cost-effective solutions that streamline the path to market for biopharmaceutical products. It is imperative that contract development manufacturing organizations (CDMO) also find solutions that align with that same sense of urgency without compromising quality or volume.

Vetter Pharma International GmbH Managing Director Peter Soelkner (left) and Rentschler Biopharma CEP Dr. Frank Mathias

As two leading CDMOS, Vetter and Rentschler Biopharma we are both committed taking on this challenge by simplifying processes, reducing complexity, and optimizing time-to-market while maintaining their high-quality standards and sustainable support of their clients’ needs. As such, we are pleased to announce a strategic collaboration aimed at achieving long-term value for our clients through the alignment of manufacturing approaches. This alliance will combine complementary skills and experience along the biopharmaceutical value chain, allowing our organizations to leverage our respective strengths, industry expertise, and core competencies, collaboratively enhance our services, and enabling our clients to bring their products to patients more easily and faster.

Supporting clients through a collaborative, complementary partnership

Both Vetter and Rentschler believe in thinking outside the box. Pursuing innovative, future-focused ideas is part of both our companies’ DNA. This new alliance is yet another example of that commitment, one that leverages the alignment of Vetter’s core competency in aseptic fill and finish and secondary packaging and Rentschler Biopharma’s experience in bioprocess development and drug substance production.

“We believe this strategic collaboration represents a great opportunity to provide valuable market foresight and reduce process complexity for our clients worldwide.”

Dr. Frank Mathias, CEP Rentschler Biopharma & Peter Soelkner, Managing Director Vetter

As a first step, we have already begun working to identify opportunities for early and active exchange of knowledge and best practices in the coming months. Some of the opportunities that will be explored through this collaboration include:

• Optimizing interfaces and early-stage communications
• Aligning client questionnaires to provide early access to product facts and timelines
• Simplifying key structures, processes, and activities
• Streamlining processes from early clinical development through delivery of commercial products
• Sharing early visibility into manufacturing requirements

As this collaboration develops, both companies will continue to independently support new and existing clients while exploring opportunities for cooperative integration of our manufacturing approaches. The important synergies between our businesses will enable us to deliver new efficiencies, simplify the supply chain, and streamline product development in ways that address many of the challenges of complexity facing companies across our industry – and ways that positively impact our clients’ business and patients’ treatment. This synergistic endeavor will be further validated in the form of pilot client projects with joint teams from both companies.

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a global leading CDMO with production facilities in Germany and the United States. Currently employing 5,000 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support, including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes, and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>